Clinical trials: Biochemically Recurrent Prostate Carcinoma, open to volunteers
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04423211
- Testing
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography
- Where
- 341 sites in United States
- Volunteers
- 804 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal.
- Trial name
- NCT04700332
- Testing
- DCFPyL PET/CT
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Recurrent Prostate Cancer
Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
TerbinaPro is a phase II drug-repurposing study evaluating oral Terbinafine in patients with biochemical recurrence of prostate cancer after prior local treatment with curative intent.
- Trial name
- TerbinaPro (NCT07365423)
- Testing
- Terbinafine
- Where
- 11 sites in Switzerland
- Volunteers
- 42 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer, Locally Recurrent Cancer
Study on Prostate Salvage Using High-dose-rate Brachytherapy
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and…
- Conditions
- Prostate Cancer, Locally Recurrent Cancer, Biochemically Recurrent Prostate Carcinoma, Toxicity Radiation
- Trial name
- PROSCATE (NCT07860528)
- Where
- 10 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with…
- Conditions
- Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
- Trial name
- DIVINE (NCT06378866)
- Testing
- Abiraterone, Apalutamide, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 532 people
- Sponsor
- Mayo Clinic
Recurrent Prostate Cancer, Prostate Cancer
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
Background: Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year.
- Trial name
- NCT07686380
- Testing
- N-803, ETBX-71 Vaccine, 18F-DCFPyL
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer Recurrent
PSMA-RLT in Biochemically Recurrent PCa
Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA > nadir + 2ng/ml after radiotherapy (RT)…
- Trial name
- NCT06220188
- Testing
- [177Lu]Lu-PSMA I&T
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
This phase II trial evaluates the impact of cancer therapy in the patients' home compared to in the clinic on safety, side effects, patient preference, and satisfaction in Black men with prostate cancer that has spread to nearby…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07073794
- Testing
- Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Biochemically Recurrent
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
Background: Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their early-stage disease was treated; however, at this stage, imaging scans…
- Trial name
- NCT05588128
- Testing
- 18F-DCFpyL
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following…
- Trial name
- NCT06813898
- Testing
- Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
This phase II trial studies how well an exercise program and continuous Fitbit monitoring work for managing metabolic syndrome and cardiovascular disease risk in patients with prostate cancer that has spread to other places in…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT05054296
- Testing
- Educational Intervention, Exercise Intervention, FitBit
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center